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Relationship between native papillary
muscle T1 time and severity of functional
mitral regurgitation in patients with
non-ischemic dilated cardiomyopathy
Shingo Kato1,3, Shiro Nakamori1, Sébastien Roujol4, Francesca N. Delling1, Shadi Akhtari1, Jihye Jang1,
Tamer Basha1,5, Sophie Berg1, Kraig V. Kissinger1, Beth Goddu1, Warren J. Manning1,2 and Reza Nezafat1*
Abstract
Background: Functional mitral regurgitation is one of the severe complications of non-ischemic dilated
cardiomyopathy (DCM). Non-contrast native T1 mapping has emerged as a non-invasive method to evaluate
myocardial fibrosis. We sought to evaluate the potential relationship between papillary muscle T1 time and mitral
regurgitation in DCM patients.
Methods: Forty DCM patients (55 ± 13 years) and 20 healthy adult control subjects (54 ± 13 years) were studied.
Native T1 mapping was performed using a slice interleaved T1 mapping sequence (STONE) which enables
acquisition of 5 slices in the short-axis plane within a 90 s free-breathing scan. We measured papillary muscle
diameter, length and shortening. DCM patients were allocated into 2 groups based on the presence or absence of
functional mitral regurgitation.
Results: Papillary muscle T1 time was significantly elevated in DCM patients with mitral regurgitation (n = 22) in
comparison to those without mitral regurgitation (n = 18) (anterior papillary muscle: 1127 ± 36 msec vs 1063 ±
16 msec, p < 0.05; posterior papillary muscle: 1124 ± 30 msec vs 1062 ± 19 msec, p < 0.05), but LV T1 time was
similar (1129 ± 38 msec vs 1134 ± 58 msec, p = 0.93). Multivariate linear regression analysis showed that papillary
muscle native T1 time (β = 0.10, 95 % CI: 0.05–0.17, p < 0.05) is significantly correlated with mitral regurgitant
fraction. Elevated papillary muscle T1 time was associated with larger diameter, longer length and decreased
papillary muscle shortening (all p values <0.05).
Conclusions: In DCM, papillary muscle native T1 time is significantly elevated and related to mitral regurgitant fraction.
Background
Functional mitral regurgitation, a consequence of left
ventricular (LV) remodeling despite normal mitral valve
structure, is one of the common and severe complications
in non-ischemic dilated cardiomyopathy patients (DCM)
[1–4]. It has been reported that the annular enlargement
and mitral leaflet tethering by the displacement of papillary
muscles due to LV dilatation are the main mechanisms of
functional mitral regurgitation [5]. To date, little is known
regarding the relationship between papillary muscle func-
tion and mitral regurgitant fraction in DCM patients.
Native (non-contrast) T1 mapping has emerged as a car-
diovascular magnetic resonance (CMR) method to assess
LV diffuse myocardial fibrosis [6]. Studies have shown that
native T1 mapping detects diffuse myocardial abnormalities
in hypertrophic cardiomyopathy and DCM [7–9]. The
extent of myocardial damage by acute myocardial infarc-
tion can also be accurately assessed by native T1 mapping
[10]. Diffuse myocardial abnormalities in patients with car-
diac amyloidosis [11] and Anderson-Fabry disease [12, 13]
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can be assessed by native T1 mapping. However, data is
lacking regarding native T1 mapping of papillary muscles
in these myopathies, including DCM.
Therefore, we sought to examine papillary muscle native
T1 mapping in DCM and to investigate the relationship
between papillary muscle native T1 time and functional
mitral regurgitation in this population.
Methods
Study subjects
Forty DCM patients (55 ± 13 years; 31 male) and 20
healthy adult control subjects (54 ± 13 years; 13 male)
free of any cardiovascular diseases were studied. All
participants were in sinus rhythm at the time of scan.
CMR acquisition
CMR was performed using a 1.5 T system and a 32-
channel cardiac phased array receiver coil (Achieva,
Philips Healthcare, Best, The Netherlands). Cine CMR,
phase contrast images of the ascending aorta, T1 mapping
and 3 dimensional late gadolinium enhancement (LGE)
were obtained in all participants [14]. T1 mapping was
performed using a free-breathing slice-interleaved T1
(STONE) sequence [15].
Electrocardiogram monitoring leads were positioned
with the subject in the supine position. Vertical and hori-
zontal LV long-axis cine images were acquired using a
steady-state free precession (SSFP) sequence. LV volumes
and mass were calculated from an LV short-axis stack of
cine images extending from the apex to the base (repetition
time (TR), 3.3 ms; echo time (TE), 1.6 ms; flip angle (FA),
60°; field-of-view (FOV), 320 × 320 mm; acquisition matrix,
128 × 128; slice thickness, 8 mm; gap, 2 mm) [16]. Phase
contrast images were acquired perpendicular to the prox-
imal ascending aorta to quantify blood flow by following
parameters (TR, 15 ms; TE, 6.5 ms; FA, 30°; velocity en-
coding, 300 cm/s; FOV, 320 × 320 mm; acquisition matrix,
288 × 288; number of phases per cardiac cycle, 36). STONE
native T1 mapping was acquired in the short axis during
free-breaching using slice-tracking with a balanced SSFP
readout (5 slices, TR/TE = 2.8/1.4 msec, flip angle = 70,
FOV = 360 × 351 mm, voxel size = 2.1 × 2.1 mm, slice
thickness = 8 mm, TFE factor = 86, SENSE factor = 2).
Fifteen minutes after the injection of 0.2 mmol/kg gadobe-
nate dimeglumine, LGE images were acquired using a 3
dimensional sequence [14] with following parameters (TR,
5.3 ms; TE, 2.1 ms; FA, 70°; FOV, 320 × 320 × 125 mm3;
acquisition matrix, 224 × 224 × 23; spatial resolution,1.4 ×
1.4 × 1.5 mm; reconstruction resolution, 0.6 × 0.6 × 0.8 mm).
Image analysis
Data were analyzed using a commercial workstation (Extend
MR WorkSpace, version 2.3.6.3, Philips Healthcare). To
determine LV mass, epi- and endocardial LV borders were
manually traced on the short axis images. LV mass was cal-
culated as the sum of the myocardial volume multiplied by
the specific gravity (1.05 g/mL) of myocardial tissue [17].
Left atrial (LA) volume was calculated using biplane area
length method [18]. Papillary muscle morphology
(diameter, length and shortening), anterior and poster-
ior mitral leaflet length, mitral annulus diameter (both
in 2 chamber and 4 chamber views) and tenting height
were measured by cine CMR (Fig. 1). Papillary muscle
shortening was calculated as follows.
Papillary muscle shortening %ð Þ
¼ ½maximum papillary muscle length mmð Þ
–minimum papillary muscle length mmð Þ
=maximum papillary muscle length mmð Þ  100
Aortic blood flow was determined using the semi-
automated algorithms [19]. Phase offset correction was
performed as described previously [20]. Mitral regurgita-
tion volume was calculated as the difference between the
LV stroke volume and ascending aorta forward flow [21].
Mitral regurgitant fraction was calculated as follows.
Mitral regurgitant fraction %ð Þ
¼ ½LV stroke volume mLð Þ
–ascending aorta forward flow mLð Þ
=LV stroke volume mLð Þ  100
For calculating papillary muscle native T1 time, both an-
terior and posterior papillary muscles were manually
traced on custom software (MediaCare, Boston, MA,
USA) (Fig. 2). For calculating LV native T1 time, the three
short axis LV slices were then divided into 6 segments for
base and mid slices, 4 segments for apical slice using the
anterior right ventricular-LV insertion point as reference.
The 16 segment model was used to assess native T1 time
in each segments. The native T1 time from all the seg-
ments was averaged to calculate each subjects LV T1 time.
Motion correction was performed using the adaptive regis-
tration of varying contrast-weighted images for improved
tissue characterization (ARCTIC) approach [22]. To evalu-
ate inter-observer variability, measurements of papillary
muscle native T1 time from 10 DCM patients and 10
healthy adult controls were independently taken by two
observers. One of the two observers measured papillary
muscle native T1 time twice to assess intra-observer vari-
ability. The time delay between two read for intra-observer
variability was 1 month. Visual assessment was performed
to evaluate for LV and papillary muscle scar on LGE.
Statistical analysis
Data were analyzed using SPSS software (version 17.0,
SPSS, Inc., Chicago, IL, USA) and MedCalc for Windows
(version 14.8.1, MedCalc Software, Ostend, Belgium).
Continuous values are presented as mean ± standard
deviation (SD). Categorical values are expressed as
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number (%). DCM patients were divided into 2 groups
based on the presence or absence of mitral regurgitation.
To assess the difference between 3 groups (DCM patients
with mitral regurgitation, n = 22; DCM patients without mi-
tral regurgitation, n = 18; control subjects, n = 20), one-way
analysis of variance (ANOVA) with Tukey’s correction was
used for continuous variables. Chi-square test was used to
assess the difference for categorical variables. Bland and
Altman plot [23], coefficient of variation (CV) were used to
evaluate intra- and inter-observer variability for measuring
papillary muscle native T1 time. Repeatability coefficients
were calculated as 1.96 times the SD of the differences on
the Bland-Altman plots. Spearman’s correlation coefficient
was calculated to evaluate relationship between papillary
muscle T1 time and papillary muscle morphology (diameter,
length and shortening). Multivariate linear regression
analysis was performed to identify the determinants of
mitral regurgitation severity in DCM patients. Variables
with p-value <0.05 in the univariable analysis were
included in the multivariable linear regression analysis
(stepwise method). P value <0.05 was considered as
statistically significant.
Results
Patients’ characteristics
Table 1 summarizes the clinical characteristics of study
subjects. There was no significant difference in gender,
age, body mass index, systolic and diastolic blood pres-
sure, heart rate between 3 groups. Information of med-
ical therapy was also shown in Table 1.
Cine MRI and LGE findings
Table 2 summarizes CMR findings. LV end-diastolic
volume index, LV end-systolic volume index, LV mass
index were significantly higher (all p < 0.05) in DCM pa-
tients in comparison to controls. Stroke volume index and
LV ejection fraction were significantly decreased (p < 0.05)
Fig. 2 Measurement of native T1 time of papillary muscles. Location of
anterior and posterior papillary muscle T1 measurement. Blue circle
represents region of interest for T1 measurement. ROI region of interest
Fig. 1 Measurement of papillary muscle, mitral annulus and tenting height. (a) posterior papillary muscle length measurement, (b) mitral annulus
and tenting height measurement, (c) papillary muscle diameter measurement, (d) anterior papillary muscle length measurement
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Table 1 Characteristics of study subjects
DCM MR (+), N = 22 DCM MR (-), N = 18 Controls, N = 20 * P-value
DCM MR (+)
vs DCM MR (-)
* P-value
DCM MR (+)
vs Controls
* P-value
DCM MR (-)
vs Controls
Demographics
Male, % 15 (68 %) 16 (89 %) 13 (65 %) 0.12 0.83 0.083
Age, years 52 ± 16 58 ± 13 54 ± 13 0.32 0.98 0.44
Height, cm 176 ± 9 175 ± 8 172 ± 8 0.99 0.41 0.52
Body weight, kg 93 ± 20 86 ± 15 79 ± 15 0.47 0.10 0.67
BMI, kg 30 ± 7 28 ± 6 27 ± 4 0.51 0.21 0.86
BSA, m2 2.1 ± 0.3 2.0 ± 0.2 1.9 ± 0.2 0.58 0.10 0.57
SBP, mmHg 116 ± 14 119 ± 17 119 ± 12 0.80 0.70 0.99
DBP, mmHg 70 ± 11 74 ± 14 71 ± 10 0.53 0.70 0.59
Heart rate, bpm 76 ± 12 73 ± 12 68 ± 14 0.77 0.14 0.47
Medications
Aspirin 7 (32 %) 7 (39 %) - 0.64 - -
ACE/ARBs 18 (82 %) 16 (89 %) - 0.38 - -
Calcium channel blockers 2 (9 %) 2 (11 %) - 0.83 - -
Beta blockers 17 (77 %) 14 (78 %) - 0.97 - -
Diuretics 11 (50 %) 7 (39 %) - 0.48 - -
Aldosterone inhibitors 2 (9 %) 1 (6 %) - 0.67 - -
Statin 9 (41 %) 9 (50 %) - 0.57 - -
Warfarin 5 (8 %) 2 (11 %) - 0.90 - -
*P value was calculated by one-way ANOVA with Tukey’s correction or Chi-square test
ACE angiotensin converting enzyme inhibitor, ANOVA analysis of variance, ARB angiotensin receptor blocker, BMI body mass index, BSA body surface area,
DBP diastolic blood pressure, DCM dilated cardiomyopathy, HR heart rate, MR mitral regurgitation, SBP systolic blood pressure
Table 2 Comparison of CMR parameters
DCM MR (+), N = 22 DCM MR (-), N = 18 Controls, N = 20 * P-value
DCM MR (+)
vs DCM MR (-)
* P-value
DCM MR (+)
vs Controls
* P-value
DCM MR (-)
vs Controls
Cine MRI parameters
EDVI, mL/m2 129 ± 43 122 ± 36 80 ± 16 0.79 <0.05 <0.05
ESVI. mL/m2 89 ± 43 84 ± 36 32 ± 10 0.86 <0.05 <0.05
SVI, mL/m2 40 ± 11 38 ± 10 48 ± 10 0.86 0.04 0.02
LVEF, % 34 ± 13 33 ± 11 61 ± 4 0.98 <0.05 <0.05
LVMI, g/m2 67 ± 23 68 ± 17 46 ± 9 0.99 <0.05 <0.05
RVEF, % 52 ± 10 52 ± 14 58 ± 5 1.00 0.15 0.18
LA dimension, mm 58 ± 9 55 ± 7 52 ± 9 0.59 0.06 0.41
LA area (2 chamber view), cm2 29 ± 9 25 ± 6 - 0.21 - -
LA area (4 chamber view), cm2 28 ± 9 23 ± 6 - 0.07 - -
LA volume (ml) 125 ± 54 92 ± 31 - 0.04
RA dimension, mm 51 ± 10 52 ± 9 55 ± 9 0.98 0.42 0.58
LGE findings
LV LGE 3 (15 %) 5 (27 %) 0 (0 %) 0.27 0.09 0.01
Papillary muscle LGE 0 (0 %) 0 (0 %) 0 (0 %) - - -
*P value was calculated by one-way ANOVA with Tukey’s correction or Chi-square test
ANOVA analysis of variance, CMR cardiovascular magnetic resonance, DBP diastolic blood pressure, DCM dilated cardiomyopathy, EDV end-diastolic volume,
EDVI end-diastolic volume index, EF ejection fraction, ESV end-systolic volume, ESVI end-systolic volume index, HR heart rate, LGE late gadolinium enhancement,
LV left ventricle, LVMI left ventricular mass index, MR mitral regurgitation
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in DCM patients compared to control subjects. LA vol-
ume was significantly higher in DCM patients with MR
compared to those without MR (p = 0.04). LGE of LV
myocardium was observed in 8 of 40 (20 %) DCM
patients, while no DCM patients had LGE of the papillary
muscles. Healthy control subjects did not show any LGE
in the LV or the papillary muscles. Table 3 shows compari-
son of papillary muscle parameters. Papillary muscle was
significantly thicker, longer in DCM patients in com-
parison to healthy controls. Regarding mitral annulus
diameter, papillary muscle shortening and tenting height,
significant difference was also observed between DCM
patients with mitral regurgitation and those without mitral
regurgitation. Table 4 summarizes the intra- and inter-
observer variability for measurement of papillary muscle
size. Intra class correlation coefficients for papillary
muscle size measurement were >0.80 both for intra- and
inter-observer variability.
Comparison of papillary muscle T1 time between
cardiomyopathy and healthy control subjects
Figure 3 illustrates individual papillary muscle and LV T1
time for 3 groups. Mean anterior papillary muscle T1 time
was 1127 ± 36 msec for DCM with mitral regurgitation (p
< 0.05 vs DCM without mitral regurgitation; p < 0.05 vs
healthy controls), 1063 ± 16 msec for DCM without mitral
regurgitation (p = 0.29 vs healthy controls) and 1051 ±
20 msec for healthy controls. Mean posterior papillary
muscle T1 time was 1124 ± 30 msec for DCM with mitral
regurgitation (p < 0.05 vs DCM without mitral regur-
gitation; p < 0.05 vs healthy controls), 1062 ± 19 msec for
DCM without mitral regurgitation (p = 0.51 vs healthy
controls) and 1053 ± 25 msec for healthy controls. LV
native T1 time was significantly elevated in DCM patients
in comparison to healthy controls (p < 0.05, Fig. 3), but
similar between DCM patients with mitral regurgitation
and those without mitral regurgitation (1129 ± 38 msec vs
1134 ± 58 msec, p = 0.93). Figure 4 demonstrates regional
LV native T1 time in each segments. There was no
substantial variability across 16 segments both in DCM
patients and controls. In addition, there was no significant
correlation between papillary muscle T1 time and mid-
level LV T1 time (r = 0.31, p = 0.05 by Spearman’s cor-
relation coefficient). There was no significant difference
in T1 time between base, mid and apical slices (base,
1125 ± 52 msec; mid, 1130 ± 47 msec; apex, 1138 ±
54 msec, p = 0.53 by one-way ANOVA). Figure 5 shows
the relationship between papillary muscle T1 time and
papillary muscle morphology. Elevated papillary muscle
T1 time was associated with increased papillary muscle
diameter, increased papillary muscle length and de-
creased papillary muscle shortening.
Relationship between papillary muscle T1 time and mitral
regurgitant fraction
Figure 6 shows the relationship between papillary muscle
T1 time and mitral regurgitant fraction in DCM patients.
Mitral regurgitant fraction was significantly correlated
Table 3 Comparison of papillary muscle related parameters
DCM MR (+), N = 22 DCM MR (-), N = 18 Controls, N = 20 * P-value
DCM MR (+)
vs DCM MR (-)
* P-value
DCM MR (+)
vs Controls
* P-value
DCM MR (-)
vs Controls
Maximum anterior PAP diameter, mm 11.6 ± 3.3 10.2 ± 1.5 7.9 ± 1.3 0.14 <0.05 <0.05
Minimum anterior PAP diameter, mm 7.9 ± 1.9 7.6 ± 1.4 6.8 ± 0.5 0.73 <0.05 0.19
Maximum posterior PAP diameter, mm 10.6 ± 3.1 9.3 ± 1.5 7.0 ± 0.6 0.14 <0.05 <0.05
Minimum posterior PAP diameter, mm 6.9 ± 1.7 7.1 ± 0.9 5.0 ± 0.5 0.79 <0.05 <0.05
Maximum anterior PAP length, mm 44.7 ± 7.6 42.3 ± 6.3 34.5 ± 2.8 0.42 <0.05 <0.05
Minimum anterior PAP length, mm 37.6 ± 6.8 31.6 ± 5.4 23.5 ± 2.9 <0.05 <0.05 <0.05
Maximum posterior PAP length, mm 40.9 ± 8.4 37.8 ± 5.8 32.9 ± 3.1 0.28 <0.05 <0.05
Minimum posterior PAP length, mm 33.7 ± 7.3 27.9 ± 3.5 22.6 ± 3.1 <0.05 <0.05 <0.05
Anterior PAP shortening, % 15.8 ± 4.4 25.5 ± 4.1 32.0 ± 4.8 <0.05 <0.05 <0.05
Posterior PAP shortening, % 17.7 ± 5.8 26.0 ± 3.4 31.5 ± 4.9 <0.05 <0.05 <0.05
Mitral annulus (4chamber), mm 37.8 ± 6.6 32.5 ± 3.8 28.7 ± 1.1 <0.05 <0.05 <0.05
Mitral annulus (2chamber), mm 38.5 ± 4.5 34.2 ± 5.1 31.6 ± 2.0 <0.05 <0.05 <0.05
Tenting height, mm 10.3 ± 1.1 6.1 ± 1.7 2.7 ± 1.3 <0.05 <0.05 <0.05
Anterior mitral leaflet length, mm 23.6 ± 3.5 19.9 ± 2.3 21.7 ± 1.6 <0.05 0.06 0.11
Posterior mitral leaflet length, mm 13.9 ± 4.0 12.6 ± 1.9 10.4 ± 1.4 0.27 <0.05 <0.05
*P value was calculated by one-way ANOVA with Tukey’s correction
ANOVA analysis of variance, DCM dilated cardiomyopathy, MR mitral regurgitation, PAP papillary muscle
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with both anterior and posterior papillary muscle T1 time
(p < 0.05) but not with LV myocardial T1 time (p = 0.67).
Table 5 summarizes the results of multivariate linear re-
gression analysis for determinants of mitral regurgitant
fraction in all DCM patients (n = 40). In the multivariate
analysis, average of anterior and posterior papillary muscle
native T1 time was employed for analysis. Multivariate
linear regression analysis identified papillary muscle native
T1 time (β = 0.10, 95 % CI: 0.03–0.17, p < 0.05) as an
independent determinant of mitral regurgitant fraction.
Table 6 shows the results of multivariate linear regression
analysis for determinants of mitral regurgitant fraction in
DCM patients with MR (n = 22). Multivariable linear
regression analysis identified posterior papillary muscle
maximum diameter (β = 1.32, 95 % CI: 0.50–2.16, p < 0.05)
and papillary muscle native T1 time (β = 0.11, 95 % CI:
0.03–0.20, p < 0.05) as independent determinants of mitral
regurgitant fraction.
Variability of papillary muscle T1 measurement
Repeatability coefficients of anterior papillary muscle T1
time were 2.0 % for intra-observer variability, 4.1 % for
inter-observer variability. Repeatability coefficients of
posterior papillary muscle native T1 time were 1.3 % for
Table 4 Intra- and inter-observer variability for measurement of papillary muscle size
Intra observer variability Inter observer variability
ICC 95 % CI ICC 95 % CI
Maximum papillary muscle diameter 0.93 0.84–0.97 0.92 0.81–0.97
Minimum papillary muscle diameter 0.87 0.69–0.94 0.82 0.61–0.93
Maximum papillary muscle length 0.91 0.78–0.96 0.88 0.73–0.95
Minimum papillary muscle length 0.91 0.78–0.96 0.86 0.70–0.95
CI confidence interval, ICC intra class correlation coefficients
Fig. 3 Comparison of papillary muscle native T1 time and left ventricular T1 time. Papillary muscle T1 time was significantly elevated in DCM
patients with mitral regurgitation in comparison to DCM patients without mitral regurgitation and healthy controls. DCM dilated cardiomyopathy,
MR mitral regurgitation
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intra-observer variability, 5.0 % for inter-observer
variability. Variability of papillary muscle native T1 time
measurement was high (CV of intra-observer variability:
0.9 % for anterior papillary muscle and 0.7 % for poster-
ior papillary muscle; CV of inter-observer variability:
1.6 % for anterior papillary muscle and 1.8 % for poster-
ior papillary muscle).
Discussion
To the best of our knowledge, this study is the first investi-
gation to examine the feasibility and variability of papillary
muscle native T1 time measurement, and to investigate the
relationship between papillary muscle T1 time and severity
of functional mitral regurgitation in DCM patients. We
found a significant difference of papillary muscle native T1
Fig. 4 Regional left ventricular native T1 time in each segments. There was no substantial variability across 16 segments both in DCM patients
and controls. DCM dilated cardiomyopathy, MR mitral regurgitation
Fig. 5 Relationship between papillary muscle native T1 time and morphology. Papillary muscle native T1 time was correlated with papillary
muscle diameter, length and shortening
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Fig. 6 Relationship between papillary muscle native T1 time and mitral regurgitant fraction. Papillary muscle native T1 time was associated with
mitral regurgitant fraction in DCM patients. DCM dilated cardiomyopathy
Table 5 Univariate and multivariate linear regression analysis for determinants of mitral regurgitant fraction in all DCM patients (n = 40)
Univariable analysis Multivariable analysis
B 95 % CI for β P-value B 95 % CI for β P-value
Age, year −0.01 −0.20–0.18 0.90 - - -
Gender, male −3.99 −10.50–2.53 0.22 - - -
Body mass index, kg/m2 0.22 −0.21–0.71 0.28 - - -
LVEDVI, mL/m2 0.05 −0.02–0.12 0.18 - - -
LVEF, % −0.16 −0.40–0.07 0.17 - - -
LVMI, g/m2 0.06 −0.08–0.20 0.37 - - -
Left atrial area (4 chamber), cm2 0.56 0.23–0.91 <0.05 0.17 −1.05–1.39 0.25
Left atrial area (2 chamber), cm2 0.36 −0.16–0.89 0.17 - - -
Left atrial volume, cm3 0.10 0.04–0.16 <0.05 −0.01 −0.21–0.20 0.95
Mitral annulus (4 chamber), mm 0.43 −0.01–0.87 0.06 - - -
Tenting height, mm 2.28 1.38–3.17 <0.05 0.61 −0.37–1.59 0.21
Anterior papillary muscle maximum diameter, mm 1.28 0.34–2.23 <0.05 0.29 −0.59–1.16 0.51
Posterior papillary muscle maximum diameter, mm 1.37 0.35–2.38 <0.05 0.73 −0.23–1.68 0.13
Anterior papillary muscle shortening, % −0.87 −1.20– −0.54 <0.05 −0.10 −0.68–0.49 0.74
Posterior papillary muscle shortening, % −0.92 −1.24– −0.60 <0.05 −0.21 −0.75–0.32 0.42
Papillary muscle T1 time, sec 0.16 0.12–0.21 <0.05 0.10 0.03–0.17 <0.05
Variables with p value < 0.05 in univariate analysis were included in multivariable analysis
CI confidence interval, DCM dilated cardiomyopathy, LVEDVI left ventricular end-diastolic volume index, LVEF left ventricular ejection fraction, LVMI left ventricular
mass index, MR mitral regurgitation
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time between DCM patients with mitral regurgitation and
those without mitral regurgitation, a correlation between
papillary muscle native T1 time and mitral regurgitant frac-
tion in DCM patients and low variability of papillary
muscle T1 time measurement.
Papillary muscle T1 time and papillary muscle morphology
in DCM patients
Previous echocardiographic studies have shown that the
papillary muscle dysfunction is observed in several
cardiovascular diseases. Papillary muscle shortening has
been assessed using transthoracic echocardiography and
used as a functional parameter [24, 25]. In myocardial
infarction patients, papillary muscle function was
substantially reduced compared to healthy controls
(papillary muscle shortening: 15 ± 14 % vs 30 ± 8 %) [25].
Reduced papillary muscle shortening has also been re-
ported in cardiomyopathy patients including hypertrophic
cardiomyopathy or DCM [24, 26]. In the current study,
we measured papillary muscle diameter, length and
shortening using cine CMR and showed that papillary
muscle shortening was significantly reduced in DCM
patients in comparison to healthy controls. This absolute
value and difference findings were consistent with pre-
vious echocardiographic studies. In addition, we found a
significant difference in papillary muscle shortening
between DCM patients with mitral regurgitation in
comparison to those without mitral regurgitation, suggest-
ing that papillary muscle dysfunction may be contributing
to mitral regurgitation.
The maximum papillary muscle diameter was approxi-
mately 7 mm in healthy controls and 10 mm in DCM pa-
tients. Elevated papillary muscle native T1 time was
associated with larger diameter, longer length, decreased
shortening in DCM patients. This finding suggested that
papillary muscle T1 time might reflect papillary muscle
pathological changes in DCM patients (i.e. papillary muscle
fibrosis). Furthermore, papillary muscle native T1 time was
increased in DCM patients with mitral regurgitation
compared to those without mitral regurgitation, but LV
native T1 time was similar between 2 groups. These results
suggest that the papillary muscle native T1 time may be a
more sensitive for the mechanical stress induced by
functional mitral regurgitation. A previous study by
Okayama et al. showed that LGE evidence of bilateral
papillary muscle infarction correlated with LV remodeling
and functional mitral regurgitation [27]. Although the
assessment of papillary muscle abnormality is feasible by
LGE, an important advantage of non-contrast native T1
mapping is the ability to evaluate papillary muscle abnor-
mality in patients with renal dysfunction who are at high
risk of systemic nephrogenic fibrosis [28]. In addition, we
did not observe any papillary muscle LGE in this study,
suggesting that the papillary muscle pathological change is
diffuse rather than focal in DCM patients.
Table 6 Univariate and multivariate linear regression analysis for determinants of mitral regurgitant fraction in DCM patients with
MR (n = 22)
Univariable analysis Multivariable analysis
B 95 % CI for β P-value B 95 % CI for β P-value
Age, year 0.08 −0.11–0.26 0.41 - - -
Gender, male −0.49 −6.85–5.86 0.87 - - -
Body mass index, kg/m2 0.17 −0.29–0.64 0.44 - - -
LVEDVI, mL/m2 0.05 −0.02–0.11 0.17 - - -
LVEF, % −0.17 −0.40–0.05 0.12 - - -
LVMI, g/m2 0.06 −0.06–0.20 0.28 - - -
Left atrial area (4 chamber), cm2 0.34 0.01–0.68 <0.05 0.13 −0.24–0.30 0.85
Left atrial area (2 chamber), cm2 0.14 −0.21–0.49 0.42 - - -
Left atrial volume, cm3 0.05 −0.01–0.11 0.08
Mitral annulus (4 chamber), mm −0.05 −0.50–0.41 0.83 - - -
Tenting height, mm 1.46 −1.09–4.01 0.24 - - -
Anterior papillary muscle maximum diameter, mm 0.64 −0.22–1.51 0.14 - - -
Posterior papillary muscle maximum diameter, mm 0.93 0.05–1.82 <0.05 1.32 0.50–2.16 <0.05
Anterior papillary muscle shortening, % 0.31 −1.12– −0.21 0.17 - - -
Posterior papillary muscle shortening, % −0.51 −0.97– −0.05 <0.05 −0.17 −0.58–0.23 0.41
Papillary muscle T1 time, sec 0.11 0.02–0.20 <0.05 0.11 0.03–0.20 <0.05
Variables with p value < 0.05 in univariate analysis were included in multivariable analysis
CI confidence interval, DCM dilated cardiomyopathy, LVEDVI left ventricular end-diastolic volume index, LVEF left ventricular ejection fraction, LVMI left ventricular
mass index, MR mitral regurgitation
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Clinical implication
We found significant difference in papillary muscle native
T1 time between DCM patients with mitral regurgitation
and those without mitral regurgitation. However, no signifi-
cant difference was found in LV native T1 time. In addition,
papillary muscle T1 time was independently correlated with
severity of functional mitral regurgitation after adjustment
of conventional determinants, including tenting height,
mitral annulus diameter. Previous transthoracic echocar-
diographic studies showed that tenting height is a strong
indicator of effective orifice area in patents with LV dys-
function and functional mitral regurgitation [29]. Further
study is necessary to elucidate if papillary muscle native T1
time has prognostic value in DCM patients.
Study limitations
Our study has several limitations. The sample size was
modest and the study population was limited to DCM
patients and healthy controls. Our T1 mapping se-
quence, STONE, has not been histologically validated
for papillary muscle T1 mapping. Therefore, we do not
know the true cause of the elevated papillary muscle
native T1 time in DCM patients. Although T1 mapping
images acquired by STONE were motion corrected,
relatively low spatial resolution of T1 mapping images
and the partial volume effect are not negligible for T1
measurement of papillary muscle. To avoid partial vol-
ume effect with blood pool, we’ve carefully placed the
ROI on papillary muscle much smaller than actual papil-
lary muscle diameter not to include the pixels from LV
blood pool. As shown on Fig. 2, size of ROI on papillary
muscle was much smaller than actual size of papillary
muscle. The pixel size of ROI drawn on papillary muscle
was 16–40 pixels. It would be also interesting to investi-
gate the relationship between papillary muscle extra
cellular volume (ECV) and mitral regurgitant fraction.
However, calculation of ECV requires registration
between native and post-contrast T1 images, which will
be challenging for a mobile and small papillary muscle
anatomy. Regarding LV ECV, in our cohort, there were
21 DCM patients and 9 controls with ECV data. Signi-
ficant difference was found between DCM patients and
controls in LV ECV averaged over 16 segments (0.30 ±
0.04 vs 0.27 ± 0.02, p = 0.03). However, no significant dif-
ference was found between DCM patients with MR and
those without MR (0.31 ± 0.05 vs 0.29 ± 0.04, p = 0.63). A
larger, more diverse study is required to assess the
clinical relevance of papillary muscle native T1 time.
Because this study is a cross-sectional study, we can’t
say any causal relationship between papillary muscle T1
time and functional mitral regurgitation. Examination of
the potential difference of the time course of T1 change
in the myocardium and papillary muscle would also be
of interest, but is beyond the scope of this study.
Conclusions
Measurement of papillary muscle native T1 time is both
feasible and reproducible. This CMR approach success-
fully detects abnormal papillary muscle native T1 time in
DCM patients with functional mitral regurgitation.
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